TLSA Share Price Performance
US$1.59
0.66 (71.08%)
Price US$1.59
Share Pricen/a
Tiziana Life Sciences Ltd Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
TLSA Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Tiziana Life Sciences Ltd Key Details
About TLSA
- Founded
- 1998
- Employees
- 9
- CEO
- WebsiteView website
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
